Newsroom.
Clinical Immunology Society (CIS) Accepts GC Biopharma USA, Inc.’s Abstract for Poster Presentation at Their National Conference
The Clinical Immunology Society (CIS) educational committee approved GC Biopharma USA, Inc.’s abstract for poster presentation at their annual conference in Denver, CO. The poster, titled “A New Manufacturing Process to Remove Thrombogenic Factors (II, VII, IX, X, and XI) from Intravenous Immunoglobulin Gamma Preparations” was to be presented at the 2020 CIS Annual Meeting held from April 2-5, 2020. Due to the COVID-19 pandemic, CIS came to the difficult decision to cancel the annual conference. Dr. Alan Huber, GC Biopharma USA, Inc.’s Director of Medical Affairs stated, “The acceptance of GC Biopharma USA, Inc.’s poster at the 2020 CIS annual meeting placed it among those submitted by many of the top academic institutions in the world.” CIS is known for the opportunities it provides with its excellent plenary speakers and outstanding science. GC Biopharma USA, Inc. will be participating in the next CIS National Conference, held in St. Louis, MO, from April 22-25, 2021.
About GC Biopharma USA, Inc.
GC Biopharma USA, Inc., Inc., headquartered in Fort Lee, NJ, established its sales, marketing, and business operations in 2018 to serve customers and patients throughout the US. Our foundation is built on the expertise of our parent company GC Biopharma, a leading biopharmaceutical company delivering plasma therapies and vaccines throughout the world. With GC Biopharma USA, Inc., GC Biopharma will further extend its footprint, bringing its expertise and legacy to the United States.
This press release may contain forward-looking statements that express the current beliefs and expectations of GC Biopharma USA, Inc.'s management. Such statements do not represent any guarantee by GC Biopharma USA, Inc. or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma USA, Inc. undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule.
